Statement of Changes in Beneficial Ownership (4)
07 October 2020 - 10:42AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
DUGGAN ROBERT W |
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc.
[
SMMT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer |
(Last)
(First)
(Middle)
611 SOUTH FORT HARRISON AVE, SUITE 306 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/2/2020 |
(Street)
CLEARWATER, FL 33756
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | | | | | | | | 42224677 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Common Stock | $3.34 | 10/2/2020 | | A | | 9730539 (1) | | (2) | (2) | Common Stock | 9730539 | (1) | 9730539 | D | |
Explanation of Responses: |
(1) | Represents the minimum number of shares that the Reporting Person shall be obligated to purchase in a private placement pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). The Purchase Agreement affords the Issuer sole discretion to place up to 14,970,060 shares of Common Stock or as few as 9,730,539 shares of Common Stock to the Reporting Person. The shares are issuable at price of $3.34 per share of Common Stock in accordance with the terms of the Purchase Agreement. |
(2) | The closing of the Purchase Agreement is anticipated to occur in approximately two weeks' time. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
DUGGAN ROBERT W 611 SOUTH FORT HARRISON AVE SUITE 306 CLEARWATER, FL 33756 | X | X | Chief Executive Officer |
|
Signatures
|
/s/ Michael Paul Donaldson, Attorney-in-Fact | | 10/6/2020 |
**Signature of Reporting Person | Date |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024